The obesity drug craze is entering its next p...

The Chinese-founded fast-fashion retailer has released financial details ahead of its long-awaited Hong Kong float. In this Viewsroom podcast, Breakingviews columnists explain how a pushback against its business model in the West may have collapsed the valuation to just $10 bln. ...  Show more

From a cyberattack on Jaguar Land Rover to state-sponsored espionage campaigns, hackers are busier than ever. In this week’s Viewsroom, Breakingviews columnists discuss how chatbots will turbocharge the threat, and whether this will revitalize or vaporize the security industry. B ...  Show more

What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ...  Show more

A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ...  Show more

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ...  Show more

The UK government is pushing back against an attempt by some members of the House of Lords to close loopholes in transparency legislation, US bank stocks fell after Moody’s cut the credit ratings of 10 midsized banks, and the FT’s Jamie Smyth explains the craze behind new ...